Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California.
VA Greater Los Angeles Healthcare System, Los Angeles, California.
Cancer Res. 2019 Oct 1;79(19):5022-5033. doi: 10.1158/0008-5472.CAN-19-0153. Epub 2019 May 29.
Epithelial cells in the field of lung injury can give rise to distinct premalignant lesions that may bear unique genetic aberrations. A subset of these lesions may escape immune surveillance and progress to invasive cancer; however, the mutational landscape that may predict progression has not been determined. Knowledge of premalignant lesion composition and the associated microenvironment is critical for understanding tumorigenesis and the development of effective preventive and interception strategies. To identify somatic mutations and the extent of immune cell infiltration in adenomatous premalignancy and associated lung adenocarcinomas, we sequenced exomes from 41 lung cancer resection specimens, including 89 premalignant atypical adenomatous hyperplasia lesions, 15 adenocarcinomas , and 55 invasive adenocarcinomas and their adjacent normal lung tissues. We defined nonsynonymous somatic mutations occurring in both premalignancy and the associated tumor as progression-associated mutations whose predicted neoantigens were highly correlated with infiltration of CD8 and CD4 T cells as well as upregulation of PD-L1 in premalignant lesions, suggesting the presence of an adaptive immune response to these neoantigens. Each patient had a unique repertoire of somatic mutations and associated neoantigens. Collectively, these results provide evidence for mutational heterogeneity, pathway dysregulation, and immune recognition in pulmonary premalignancy. These findings identify progression-associated somatic mutations, oncogenic pathways, and association between the mutational landscape and adaptive immune responses in adenomatous premalignancy..
肺损伤领域的上皮细胞可以产生不同的癌前病变,这些病变可能具有独特的遗传异常。这些病变中的一部分可能逃避免疫监视并进展为浸润性癌症;然而,可能预测进展的突变景观尚未确定。了解癌前病变的组成和相关微环境对于理解肿瘤发生和制定有效的预防和干预策略至关重要。为了确定腺瘤性癌前病变和相关肺腺癌中体细胞突变和免疫细胞浸润的程度,我们对 41 个肺癌切除标本的外显子进行了测序,其中包括 89 个癌前病变非典型性腺瘤性增生病变、15 个腺癌和 55 个浸润性腺癌及其相邻的正常肺组织。我们将同时发生在癌前病变和相关肿瘤中的非同义体细胞突变定义为进展相关突变,其预测的新抗原与 CD8 和 CD4 T 细胞浸润以及癌前病变中 PD-L1 的上调高度相关,表明存在针对这些新抗原的适应性免疫反应。每个患者都有独特的体细胞突变和相关新抗原库。总之,这些结果为肺癌前病变中的突变异质性、途径失调和免疫识别提供了证据。这些发现确定了进展相关的体细胞突变、致癌途径以及癌前病变中突变景观与适应性免疫反应之间的关联。